Per Fischer, MinervaX CEO

Phar­ma-backed Min­er­vaX rais­es €54M as it aims to move its group B Strep­to­coc­cus vac­cine in­to PhI­II

Near­ly a year af­ter rais­ing its largest fi­nanc­ing so far, the Dan­ish biotech Min­er­vaX is back with an up­sized fi­nanc­ing round of €54 mil­lion ($57.3 mil­lion) to fund late-stage work for its vac­cine against group B Strep­to­coc­cus, the com­pa­ny an­nounced Wednes­day.

Group B Strep­to­coc­cus is a bac­te­ria re­spon­si­ble for near­ly 50% of all life-threat­en­ing in­fec­tions in new­borns. It can al­so lead to oth­er prob­lems in preg­nan­cy, like still­births, ac­cord­ing to Min­er­vaX.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.